Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Plasma Cell Myeloma Clinical Trial

Official title:

A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02700841
• Other study ID #: 0669-19-FB
• Secondary ID: NCI-2015-00743
• Status: Terminated
• Phase: Phase 2
• Start date: January 9, 2020
• Est. completion date: December 21, 2022

Study information

• Verified date: March 2024
• Source: University of Nebraska
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and post-transplant. The primary end point will be tetanus vaccine immune responses post-transplant.

Description:

PRIMARY OBJECTIVES:

1. To compare the cellular and humoral vaccine response post-transplant between the two arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays

2. To determine the feasibility and safety of this approach

SECONDARY OBJECTIVES:

1. To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19, NK, γδ T-cells), in addition to T-cell phenotype markers between the two arms.

2. To compare post-transplant recovery of T-regs and MDSCs between the two arms.

3. To compare progression free survival (PFS) at 2 years post-transplant

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 21, 2022
• Est. primary completion date: December 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age = 19 years to 70 years old at time of study entry (consent)

2. Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group (IMWG) criteria .

3. Must have measurable disease defined as: for secretory MM, serum monoclonal protein =1.0 g/dL, urine monoclonal protein =200 mg/24 hrs, and involved free light chain = 10 mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage =30%.

4. Must have standard risk myeloma (see exclusion criterion 4).

5. Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary clinically for cytoreduction)

6. Able to understand and sign a consent form.

7. Creatinine clearance equal or > 60 ml/min (calculated)

8. Ejection fraction equal or > 50% before admission for transplant as per institutional standards. Patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to be cleared by cardiology as per institutional BMT standards.

9. Serum bilirubin, ALT, AST less than 3 X upper limit of normal

10. FVC, FEV1 or DLCO >50% predicted before admission for transplant as per institutional standards. Patients on home oxygen are not allowed on the protocol.

11. No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of the start of the induction therapy).

12. KPS = 70%or ECOG 0-2.

13. Must be eligible to receive Melphalan dose of 200mg/m2

14. A female of child-bearing potential, must have two negative urine pregnancy test results within 10 to 14 days prior to starting the first dose of vaccine pre-transplant as a way of ensuring safe transplant planning.

Exclusion Criteria:

1. Participation in another clinical study with an investigational product during the last 28 days.

2. Prior stem cell transplant (either autologous or allogeneic)

3. Creatinine clearance < 60 ml/min (calculated)

4. High risk MM defined as those with the following disease, fluorescence in situ hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14), t(14;16), t(14;20), >1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell leukemia (primary or secondary), or subjects who failed to achieve =PR to induction therapy (i.e. VRd) and required salvage induction prior to AHSCT.

5. Documented central nervous system or extramedullary disease.

6. Significant organ dysfunction deemed to carry inappropriate risk for AHSCT.

7. Intention or plans for cyclophosphamide mobilization.

8. Known allergic reactions after previous tetanus diphtheria vaccination or had a condition of Guillain Barre Syndrome (GBS)

9. Known active hepatitis B, C or HIV infections on initial assessment.

10. Enrollment on any other transplant related protocols.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma
• Tetanus

Intervention

Drug:
• Melphalan
Given IV

Procedure:
• Peripheral Blood Stem Cell Transplantation--CD34 HSCT
Undergo autologous CD34 HSCT
• Peripheral Blood Stem Cell Transplantation--AHSCT
Undergo AHSCT

Biological:
• T Cell-Depleted Hematopoietic Stem Cell Transplantation
Undergo autologous CD34 HSCT
• Tetanus Toxoid Vaccine
Given IM

Locations

Country	Name	City	State
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Safely Treated Participants (Feasibility and Safety)	Determine safety of outcomes based on the number of safely treated participants by CTCAE version 5.0 tool	Through 180 days post-transplant